Clinical trial
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
NCT00312013 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00312013 |
|---|---|
| Title | Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer |
| Official title | A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thrombosis, Venous |
| Intervention type | Drug |
| Interventions | Nadroparin |
| Enrollment | 503 |
| Start date | May 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Apr 7, 2006 |
| Last update posted | Mar 23, 2017 |
| Countries | Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, Poland, Russia, Slovenia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: